Enhanced quality of life
We back ideas which have the potential to enhance quality of life across the nation, and beyond.
We have over £100 billion in high level knowledge assets in the public sector ripe for use in a diverse range of applications.
Alongside the Government Office for Technology Transfer, we nurture and invest in assets via spin-out companies which can boost public sector productivity, deliver economic gains and improve quality of life in the UK.
We back ideas which have the potential to enhance quality of life across the nation, and beyond.
We support the commercialisation of knowledge assets which can be used in a diverse range of applications.
The UK has over £100 billion in high level knowledge assets, which we must exploit to drive economic growth.
Sona, from the world-leading National Physical Laboratory (NPL), will revolutionise breast cancer screening with the world’s first innovative ultrasound-based breast density assessment and monitoring technology, that does not require imaging or trained radiologists.
Sona aims to create a new standard in breast cancer risk assessment and early detection. With its compact form, Sona’s simple, low-cost device is positioned for deployment in medical practices, local health clinics and primary care sites, expanding early breast cancer risk assessment capabilities across socioeconomic boundaries. This approach contributes to the UK’s objectives of reducing health inequalities by making healthcare more accessible to all women, regardless of background or location.
With a £250K grant funding from GOTT supporting Sona’s product development, UKI2S’s investment of £200K will be used to build the team and business plan in preparation for the 2025 spinout, and engage customers to test and adopt the miniaturised desktop version of Sona’s technology.
As the UK healthcare system struggles to keep pace with the Antimicrobial Resistance (AMR) crisis (identified by the World Health Organisation as one of the top 10 global public health threats), Presymptom Health’s AI-driven AMR tests could revolutionise its detection, diagnosis and treatment, saving countless lives.
"We’re confident that our first product can play a big part in tackling Antimicrobial Resistance (AMR). By understanding the presence, or absence, of infection as early as possible, doctors can be more confident in their diagnosis and avoid unnecessarily prescribing antibiotics — something that is a growing concern in the NHS and globally. This funding will help us enter the market by 2025 and, ultimately, save lives sooner. We will initially roll-out in the UK, but have plans for the US and beyond in the following years."
Read on for the latest news, advice, opinions and tech emerging from the UK’s public sector.
© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.
